Open AccessAmbrisentan for treatment of inoperable chronic thromboembolic pulmonary hypertension (CTEPH)
Author(s) -
EscribanoSubias Pilar,
Bendjenana Hakim,
Curtis Paula S.,
Lang Irene,
Noordegraaf Anton Vonk
Publication year - 2019
Publication title -
pulmonary circulation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.791
H-Index - 40
ISSN - 2045-8940
DOI - 10.1177/2045894019846433
Subject(s) - ambrisentan , medicine , chronic thromboembolic pulmonary hypertension , placebo , clinical endpoint , pulmonary hypertension , adverse effect , randomized controlled trial , bosentan , receptor , alternative medicine , pathology , endothelin receptor
This multicenter, randomized, double‐blind, placebo‐controlled study assessed ambrisentan or placebo in patients with inoperable chronic thromboembolic pulmonary hypertension. Futility of enrollment led to early termination. Trends of improvement in favor of ambrisentan versus placebo in the primary and some secondary endpoints were observed; adverse event profiles were similar between groups.